①For stage IV non-small cell lung cancer with EGFR-sensitive mutations, first-line treatment with gefitinib or erlotinib is recommended. ②For stage IV non-small cell lung cancer with EGFR wild-type or unknown mutation status, systemic chemotherapy with platinum-containing two-drugs should be started as early as possible if the functional status score is PS=0 to 1. Non-platinum two-drug combination chemotherapy may be considered for patients who are not candidates for platinum-based therapy. ③Current evidence does not support the use of age factors as a basis for selecting chemotherapy regimens. ④For non-small cell lung cancer that has failed first-line chemotherapy, second-line chemotherapy with doxorubicin and pemetrexed, and second- or third-line oral therapy with gefitinib or erlotinib are recommended. ⑤ Stage IV non-small cell lung cancer with a score of PS>2 may be treated with best supportive care only, as appropriate. ⑥ Appropriate local treatments (e.g. radiotherapy) can be chosen for specific local conditions on top of systemic treatment to improve symptoms and quality of life.